In the following video, Motley Fool health care analyst Brenton Flynn discusses Bausch & Lomb and the scuttlebutt surrounding a potential acquirer. He talks about Abbott Labs , Johnson & Johnson , Sanofi , Pfizer , and Merck , and just how realistic this purchase would be for each. He also gives his bet on which company, in the end, may be the buyer.
Instead of speculating on buyouts, get the inside scoop on what Motley Fool Superinvestor David Gardner will be buying this year. He's crushed the market in his Stock Advisor and Rule Breakers portfolios for years, and now I invite you to a personal tour of his flagship stock picking service: Supernova. Just click here now for instant access.
The article Big Pharma's New Battle for Eyeballs originally appeared on Fool.com.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.